Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy

33Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. Previously, we have found that pravastatin prevents diabetic nephropathy in streptozotocin-induced diabetic rats independently of serum lipid levels. The aim of this study was to clarify the impact of pravastatin on the mesangial cells exposed to high glucose. Methods. Rat mesangial cells were cultured in DMEM containing low glucose (5 mM glucose), high glucose (25 mM glucose) and 25 mM glucose with 500 μM pravastatin for 48 hours, respectively. After harvesting, we examined membrane-associated Ras with immunoblot analysis, activity of mitogen-activated protein kinase (MAPK) in the cytosol fraction with in-gel kinase assay and expressions of TGF-β mRNA with Northern blot analysis. Results. Membrane-associated Ras, activity of MAP kinase, and expression of transforming growth factor-β (TGF-β) mRNA were increased in the mesangial cells cultured exposed to high glucose compared to low glucose. Pravastatin suppressed all these changes in membrane-associated Ras, MAP kinase and TGF-β mRNA in high glucose. Conclusions. This study suggests that pravastatin suppresses the activity of Ras-MAP kinase cascade and induction of TGF-β in the mesangial cells that have been exposed to high glucose. © 1999 by the International Society of Nephrology.

Cite

CITATION STYLE

APA

Yokota, T., Utsunomiya, K., Murakawa, Y., Kurata, H., & Tajima, N. (1999). Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney International, Supplement, 56(71). https://doi.org/10.1046/j.1523-1755.1999.07146.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free